切换至 "中华医学电子期刊资源库"

中华消化病与影像杂志(电子版) ›› 2023, Vol. 13 ›› Issue (06) : 399 -403. doi: 10.3877/cma.j.issn.2095-2015.2023.06.007

论著

中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析
胡宝茹, 尚乃舰(), 高迪   
  1. 150000 哈尔滨医科大学附属肿瘤医院影像中心
  • 收稿日期:2023-07-15 出版日期:2023-12-01
  • 通信作者: 尚乃舰

DCE-MRI and DWI findings of advanced hepatocellular carcinoma and their correlation with prognosis after immunotherapy

Baoru Hu, Naijian Shang(), Di Gao   

  1. Image Center, Harbin Medical University Cancer Hospital, Harbin 150000, China
  • Received:2023-07-15 Published:2023-12-01
  • Corresponding author: Naijian Shang
引用本文:

胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.

Baoru Hu, Naijian Shang, Di Gao. DCE-MRI and DWI findings of advanced hepatocellular carcinoma and their correlation with prognosis after immunotherapy[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 399-403.

目的

基于中晚期肝细胞癌患者免疫治疗前后的磁共振动态增强(DCE-MRI)及弥散加权成像(DWI)表现,探讨DCE-MRI及DWI在中晚期肝细胞癌预后评估中的应用价值。

方法

收集2018年1月至2022年7月于哈尔滨医科大学附属肿瘤医院行免疫治疗的100例中晚期肝细胞癌患者的病历资料进行回顾性分析,免疫治疗前及治疗结束后均行DCE-MRI及DWI扫描,出院后进行定期随访,分析DCE-MRI及DWI表现与免疫治疗预后的相关性。

结果

100例患者随访期间死亡63例,生存37例,总生存率为37%,中位生存期为19个月。MRI特征表现:肿块边缘不规则;病灶边缘呈"快进快出"型强化;较大的病灶,往往信号不均匀,表明有坏死、液化、出血或钙化存在;DWI扩散受限。生存组与死亡组在肿瘤数目、肿块边缘、有无"快进快出"型强化、内部坏死及DWI扩散受限方面比较,差异均有统计学意义(P<0.05)。Cox多因素回归分析显示,肿块边缘不规则、有"快进快出"型强化、有内部坏死及DWI扩散受限是影响中晚期肝细胞癌患者免疫治疗预后生存的独立危险因素(P<0.05)。

结论

中晚期肝细胞癌的DCE-MRI及DWI表现中,肿块边缘不规则、有"快进快出"型强化、有内部坏死、DWI扩散受限与免疫治疗预后密切相关。

Objective

To explore the application value of dynamic contrast-enhanced MRI(DCE-MRI)and diffusion-weighted imaging(DWI)in prognosis evaluation in advanced hepatocellular carcinoma based on DCE-MRI and DWI findings before and after immunotherapy.

Methods

A retrospective analysis was performed on the case data of 100 patients with advanced hepatocellular carcinoma who underwent immunotherapy in Harbin Medical University Cancer Hospital between January 2018 and July 2022.All patients underwent DCE-MRI and DWI scans before and after immunotherapy, and they were regularly followed up after discharge.The correlation between DCE-MRI, DWI findings and prognosis after immunotherapy was analyzed.

Results

In the 100 patients during follow-up, there were 63 death cases and 37 survival cases.The overall survival rate and median survival time were 37% and 19 months, respectively.MRI findings: irregular edges in tumors, fast-in and fast-out enhancement in lesion edges.For larger lesions, there were often uneven signals, indicating necrosis, liquefaction, bleeding or calcification.There was limitation of DWI diffusion.There were significant differences in number of tumors, tumor edges, fast-in and fast-out enhancement, internal necrosis and limitation of DWI diffusion between the survival group and the death group(P<0.05). The results of Cox multivariate regression analysis showed that irregular edges in tumors, fast-in and fast-out enhancement, internal necrosis and limitation of DWI diffusion were independent risk factors of prognosis in patients with advanced hepatocellular carcinoma after immunotherapy(P<0.05).

Conclusion

In DCE-MRI and DWI findings from patients with advanced hepatocellular carcinoma, irregular edges in tumors, fast-in and fast-out enhancement, internal necrosis and limitation of DWI diffusion are closely related to prognosis after immunotherapy.

图1 中晚期肝细胞癌患者免疫治疗预后生存曲线
表1 两组患者一般资料比较
图2 中晚期肝细胞癌患者DCE-MRI及DWI影像图注:2A蒙片,肝脏右后上段病灶信号不均匀。2B动脉晚期,病灶内见结节样强化(细箭),后缘(粗箭)强化,不能判定后缘是否有活性。2C动脉期剪影,病灶内结节(细箭)及后缘(粗箭)有强化,不能判定后缘是否有活性。2D静脉期,病灶内结节(细箭)及后缘(粗箭)强化减退。2E DWI图,病灶内结节(细箭)高信号,后缘(粗箭)低信号,提示病灶内结节有活性,后缘无活性。2F ADC图,病灶内结节(细箭)低信号,后缘(粗箭)高信号,提示病灶内结节有活性,后缘无活性。
表2 两组患者MRI特征比较(例)
表3 影响中晚期肝细胞癌患者免疫治疗预后的多因素回归分析
1
杨帆,曹毛毛,李贺,等.1990—2019年中国人群肝癌流行病学趋势分析及预测[J].中华消化外科杂志202221(1):106-113.
2
吴徐璐,陈炜越,郑丽云,等.索拉非尼联合免疫检查点抑制剂治疗TACE抵抗的中晚期肝癌的疗效及安全性[J].肝胆胰外科杂志202133(10):585-589,595.
3
Craciun Lde Wind RDemetter P,et al.Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma:a rationale for combining selective internal radiation therapy(SIRT)and immunotherapy[J].BMC Cancer202020(1):135-139.
4
赵梦,徐兴华,王芳,等.DCE-MRI减影技术及DWI序列在原发性肝癌局部介入术后评估的应用研究[J].医学影像学杂志202030(3):414-419.
5
Hectors SJLewis SKennedy P,et al.Assessment of hepatocellular carcinoma response to 90y radioembolization using dynamic contrast material-enhanced MRI and intravoxel incoherent motion diffusion-weighted imaging[J].Radiol Imaging Cancer20202(4):190094.
6
中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].中华肝脏病杂志201725(12):886-895.
7
Llovet JMCastet FHeikenwalder M,et al.Immunotherapies for hepatocellular carcinoma[J].Nat Rev Clin Oncol202219(3):151-172.
8
El-Khoueiry ABSangro BYau T,et al.Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J].Lancet2017389(10088):2492-2502.
9
Wong JSLKwok GGWTang V,et al.Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors[J].J Immunother Cancer20219(2):1945.
10
Kudo MMatilla ASantoro A,et al.CheckMate 040 cohort 5:A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis[J].J Hepatol202175(3):600-609.
11
Hectors SJLewis SBesa C,et al.MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma[J].Eur Radiol202030(7):3759-3769.
12
Qin JZhou GSheng X,et al.Imaging features of intrahepatic bile duct adenoma in MRI[J].Transl Cancer Res20209(3):1861-1866.
13
王晶晶,邰兆琴,吴鹤林,等.MRI增强扫描在肝癌诊断及疗效评估中的应用观察[J].中国CT和MRI杂志202119(12):93-95.
14
黄泽弟,王猛,沈冰奇,等.磁共振弥散峰度成像在鉴别肝细胞癌与其他良性结节中的价值[J/OL].中华普通外科学文献(电子版)202014(3):189-194.
15
Li XQWang XZhao DW,et al.Application of Gd-EOB-DTPA-enhanced magnetic resonance imaging(MRI)in hepatocellular carcinoma[J].World J Surg Oncol202018(1):219.
16
Gatti MMaino CDarvizeh F,et al.Role of gadoxetic acid-enhanced liver magnetic resonance imaging in the evaluation of hepatocellular carcinoma after locoregional treatment[J].World J Gastroenterol202228(26):3116-3131.
17
Terroir MBorget IBidault F,et al.The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer[J].Eur J Nucl Med Mol Imaging201744(4):638-646.
[1] 丁建民, 秦正义, 张翔, 周燕, 周洪雨, 王彦冬, 经翔. 超声造影与普美显磁共振成像对具有高危因素的≤3 cm肝结节进行LI-RADS分类诊断的前瞻性研究[J]. 中华医学超声杂志(电子版), 2023, 20(09): 930-938.
[2] 张莲莲, 惠品晶, 丁亚芳. 颈部血管超声在粥样硬化斑块易损性评估中的应用价值[J]. 中华医学超声杂志(电子版), 2023, 20(08): 816-821.
[3] 岳志浩, 王晶, 闫子玉, 葛娜, 许向亮, 单小峰, 崔念晖. 牙槽外科相关舌神经损伤早期诊断及治疗中磁共振神经成像技术的应用[J]. 中华口腔医学研究杂志(电子版), 2023, 17(06): 413-417.
[4] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[5] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[6] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[7] 姜明, 罗锐, 龙成超. 闭孔疝的诊断与治疗:10年73例患者诊疗经验总结[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 706-710.
[8] 卢艳军, 马健, 白鹏宇, 郭凌宏, 刘海义, 江波, 白文启, 张毅勋. 纳米碳在腹腔镜直肠癌根治术中253组淋巴结清扫的临床效果[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 473-477.
[9] 孙钢. 超高场磁共振成像的发展现状与展望[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 369-372.
[10] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[11] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[12] 赵文毅, 邹冰子, 蔡冠晖, 刘永志, 温红. 超声应变力弹性成像联合MRI-DWI靶向引导穿刺在前列腺病变诊断中的应用[J]. 中华临床医师杂志(电子版), 2023, 17(9): 988-994.
[13] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[14] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
[15] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
阅读次数
全文


摘要